Pharmaceutical industry
Investigative teams at the Memorial Sloan-Kettering Cancer Center and Georgetown University Lombardi Cancer Research Center have reported successful Phase I/II clinical trials of Ligand Pharmaceuticals' LGD1550, a retinoic acid receptor (RAR)-selective retinoid, in advanced cancer patients. LGD1550 has demonstrated potent anti-tumor activity in pre-clinical studies and has
Pharmaceutical industry
In a recent presentation at the 34th Annual Meeting of the American Society of Clinical Oncology, Cell Therapeutics, Inc. revealed encouraging data from a Phase I clinical trial of its novel anti-cancer drug, CT-2584. The study, conducted at the Memorial Sloan-Kettering Cancer Center in New York City, aimed to establish
Drugs
Richmond, Calif., May 18, 1998 - Onyx Pharmaceuticals, Inc. announced promising results from two Phase II studies of its lead anticancer viral therapeutic, ONYX-015, in patients with tumors of the head and neck. The company reported that nine out of ten patients with recurrent tumors have experienced tumor regressions of
Drugs
Preliminary data from an investigational clinical trial with high doses of Bexxar in combination with chemotherapy and stem cell transplantation in non-Hodgkin's lymphoma patients have demonstrated the potential of Bexxar to be safely and effectively combined with chemotherapy and autologous stem cell transplantation to treat patients with relapsed
Pharmaceutical industry
Oncormed, a genomics services company, has signed an agreement with Merck & Co. to provide ras gene testing services for Phase I trials of an anti-cancer therapeutic compound. The ras gene, identified in rats over 15 years ago, is believed to play a significant role in up to 30% of
Pharmaceutical industry
Antigenics, L.L.C. announced that the U.S. Patent and Trademark Office (PTO) has issued Patent No. 5,750,119, covering the company's proprietary heat shock protein (HSP) technology for cancer treatment. This patent represents a significant milestone for Antigenics, as it is the only U.S.
Drugs
Scientists at the Human Genome Project are discovering genetic markers for various diseases, including cancer, at an unprecedented rate. The identification of these disease genes is paving the way for the development of DNA-based diagnostic and prognostic assessments. This momentum is expected to revolutionize the pharmaceutical industry, enabling the creation
Pharmaceutical industry
A novel clinical trial is enrolling 698 patients with advanced ovarian cancer to evaluate the effectiveness of combining standard chemotherapy with PSC 833, an investigational agent that may overcome chemotherapy resistance and prevent its development. The study, sponsored by Novartis, aims to recruit patients from the United States, Canada, Europe,
Pharmaceutical industry
Research on a potential cancer cure has garnered significant attention, with a recent study on mouse experiments suggesting that a combination of drugs, angiostatin and endostatin, can eradicate cancerous tumors. However, experts have expressed concerns that this enthusiasm may be premature, highlighting potential risks and limitations of the therapy in
Pharmaceutical industry
Pacific Pharmaceuticals, Inc. is set to commence a human safety study of its photodynamic therapy compound BOPP in patients with malignant brain cancer, following the US FDA's acceptance of the Company's Investigational New Drug application. The 25-30 patient clinical study will be conducted at the Royal
Pharmaceutical industry
Sparta Pharmaceuticals Inc. has signed a license agreement with Schering-Plough Corp. to apply Spartaject Technology to TEMODAL, an oral anticancer agent currently in development for the treatment of patients with recurrent malignant gliomas. The Spartaject technology allows poorly water-soluble compounds to be given by injection, encapsulating fine particles of an
Pharmaceutical industry
Palo Alto, California-based ALZA Corporation and U.S. Bioscience, Inc. have signed a marketing and distribution agreement for Ethyol(R), a cytoprotective agent for reducing kidney toxicity associated with chemotherapy. The agreement grants ALZA exclusive marketing rights in the United States for five years, with an option to extend for
